Rani Therapeutics Holdings, Inc. (RANI)


-0.11 (-5.34%)
Symbol RANI
Price $1.95
Beta 0.334
Volume Avg. 0.04M
Market Cap 103.426M
Shares () -
52 Week Range 1.8901-10.743
1y Target Est -
DCF Unlevered RANI DCF ->
DCF Levered RANI LDCF ->
ROE -153.07% Strong Sell
ROA -61.34% Strong Sell
Operating Margin -
Debt / Equity 126.42% Buy
P/E -1.52 Sell
P/B 2.05 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest RANI news

Mr. Talat Imran
NASDAQ Global Market

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.